Cabotegravir receives FDA Breakthrough for HIV prevention

The Breakthrough Therapy Designation for use in HIV pre-exposure prophylaxis for this long acting injection was based on efficacy and safety results from HPTN 083, a phase IIb/III study that compared cabotegravir to daily oral emtricitabine/tenofovir disoproxil fumarate.

Source:

Biospace Inc.